Gut microbiota dysbiosis in cirrhotic cardiomyopathy: mechanistic gut-liver-heart axis and nutritional microbiota-targeted interventions
Frontiers in Nutrition · 18.11.2026 · 13
DOI: 10.3389/fnut.2026.1847556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nutrition, online erschienen am 18.11.2026. Verfasst von Ping Yan und 4 weiteren Autor:innen. Die Arbeit nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cirrhotic cardiomyopathy (CCM) is an underdiagnosed cardiac complication of end-stage liver cirrhosis without specific targeted therapies. Gut dysbiosis is hypothesized to act as a modifiable upstream regulator along the gut-liver-heart axis. It may contribute to myocardial remodeling through metabolic, inflammatory, autoimmune, and autonomic pathways, although causal evidence specific to CCM remains insufficient. This narrative review summarizes four proposed pathogenic axes linking intestinal dysbiosis to CCM: (1) bioactive microbial metabolites, including trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), and bile acids (BAs); (2) systemic immune-inflammatory activation triggered by pathogen-associated molecular patterns (PAMPs); (3) bacterial translocation-related autoimmunity; and (4) autonomic nervous system dysregulation along the gut-brain-heart axis. We stratified these pathways into standardized evidence tiers to distinguish preclinical cardiovascular data, cross-sectional human associations, and unvalidated hypotheses. We further highlight the bidirectional vicious cycle among portal hypertension, gut dysbiosis, and CCM, the lack of CCM-specific randomized controlled trials with cardiac endpoints, and the lack of validated personalized nutritional regimens. The 2019 Cirrhotic Cardiomyopathy Consortium (CCC) established two resting-echocardiography formal diagnostic domains for definitive CCM. The older 2005 Montreal framework combined qualitative systolic and diastolic abnormalities with supportive electrophysiological features, including QTc prolongation; QTc was supportive rather than a primary diagnostic criterion. According to CCC cutoffs: (1) resting systolic dysfunction (LVEF ≤50% or absolute global longitudinal strain (GLS) < 18%); and (2) advanced diastolic dysfunction (at least 3 of 4: septal e′ < 7 cm/s, E/e′ ≥ 15, LAVI >34 mL/m 2 , and TR velocity >2.8 m/s). Blunted stress-induced contractile reserve and isolated QTc prolongation are auxiliary risk markers, not formal diagnostic criteria. Gut microbial metabolites may be evaluated only as complementary research biomarkers and cannot replace standardized cardiac diagnosis. Nutritional interventions targeting gut homeostasis remain experimental hypotheses requiring CCM-specific validation. Finally, we distinguish CCM from metabolic dysfunction-associated steatotic liver disease (MASLD)-associated heart failure with preserved ejection fraction (HFpEF), a distinct syndrome that shares metabolic, inflammatory, and microbiota-derived mechanisms but differs in hemodynamic context, diagnostic criteria, and therapeutic evidence.
Zitieren
APA
Yan, P., Tian, X., Xiong, Y., Sun, C., & Deng, C. (2026). Gut microbiota dysbiosis in cirrhotic cardiomyopathy: mechanistic gut-liver-heart axis and nutritional microbiota-targeted interventions. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1847556
Vancouver
Yan P, Tian X, Xiong Y, Sun C, Deng C. Gut microbiota dysbiosis in cirrhotic cardiomyopathy: mechanistic gut-liver-heart axis and nutritional microbiota-targeted interventions. Frontiers in Nutrition. 2026;13. doi:10.3389/fnut.2026.1847556
BibTeX
@article{Yan2026,
author = {Yan, Ping and Tian, Xiaoli and Xiong, Yongqiang and Sun, Changfeng and Deng, Cunliang},
title = {Gut microbiota dysbiosis in cirrhotic cardiomyopathy: mechanistic gut-liver-heart axis and nutritional microbiota-targeted interventions},
journal = {Frontiers in Nutrition},
year = {2026},
volume = {13},
doi = {10.3389/fnut.2026.1847556}
}
EUVIMED